Vitrusiran Reduces Risk of Death and CV Events in Patients with ATTR-CM
Key Points: ATTR amyloid cardiomyopathy, resulting from accumulation of TTR amyloid protein in the heart, leads to progressive heart failure, complicated by arrhythmias, with a significant increase in worsened quality…
Consistent Renal Benefits of Semaglutide in CKD and T2DM Patients With or Without SGLT2 Inhibitors Use. FLOW Trial
The FLOW trial showed that among patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), once-weekly subcutaneous semaglutide was superior to placebo in improving renal and CV outcomes…
Tirzepatide Reduced Apnea-hypopnea Index and Weight in Obese Patients with Moderate Sleep Apnea: SURMOUNT-OSA Trials
Obstructive sleep apnea is associated with cardiovascular complications and is seen more commonly in individuals with excess adiposity. The SURMOUNT OSA phase 3 trials evaluated the safety and efficacy of…
LENS Trial: Fenofibrate Significantly Reduced Progression of Diabetic Retinopathy vs Placebo.
- Findings from cardiovascular trials suggested that fenofibrate therapy may reduce the progression of diabetic retinopathy. - The LENS (Lowering Events in Non-proliferative retinopathy in Scotland) was a pragmatic trial…
IVUS-Guided DES Reduced MACE at 1 year Compared to Angiography-Guided PCI: IVUS-ACS Trial
Key Points: The IVUS-ACS trial assessed whether the use of intravascular ultrasound guidance, as compared with angiography guidance, improves the outcomes of percutaneous coronary intervention with contemporary drug-eluting stents in…
IVUS -DBC: IVUS-guided drug-coated balloon angioplasty improves primary patency
Key Points: One-year success rates of angioplasty in peripheral artery disease (PAD) patients were significantly higher when guided by intravascular ultrasound (IVUS) alongside angiography. IVUS, offering precise vessel measurements and…
A technology assisted Web App allowed >90% of consumers to correctly self-select for statin use and achieve clinically important LDL-C reduction
Key Points: Nonprescription statin access may help statin-eligible patients receive appropriate treatment. This prospective, actual-use study employed a Web App for participants to self-qualify for guideline-appropriate moderate intensity statin initiation…
PROACT: Enalapril Does Not Mitigate Anthracycline Toxicity in Breast Cancer and NHL
Key Points: Anthracycline toxicity is an important cause of cardiomyopathy; it is unclear whether prophylactic treatment with ACE inhibitors could mitigate this risk. In PROACT, enalapril was compared to standard…
Topical TXA Does Not Reduce Peri-Operative Seizures but Increases Risk of Transfusion in Cardiac Surgery Compared to Intravenous TXA
Key Points: IV TXA is used to prevent peri-operative bleeding in cardiac surgery, but it carries a risk of seizure. It is hypothesized that topical TXA may reduce this risk…
IMPROVE-HCM: Cardiac Mitotrope -Ninerafaxstat- Improves Functional Capacity in Symptomatic Non-Obstructive HCM
Key Points: Despite the high symptomatic burden, very few effective treatments exits for symptomatic, non-obstructive HCM. In IMPROVE-HCM, a novel cardiac mitotrope (ninerafaxstat) was compared to placebo in non-obstructive HCM.…
A Restrictive Benzodiazepine Strategy During Cardiac Surgery Does Not Reduce Post-Operative Delirium
Key Points: Benzodiazepine use contributes to delirium before and after cardiac surgery, but intra-operative benzodiazepine use has not been well-studied. In B-Free, a restrictive intraoperative benzodiazepine strategy was compared with…
TRAVERSE: Transseptal approach to LV ablation results in fewer cerebral emboli compared to retrograde aortic approach
Key Points: Among patients who undergo endocardial ablation for left ventricular arrythmias, it is uncertain whether the number of imaging-detected cerebral emboli differs based on the anatomical approach. In this…
FFR-Guided Complete Revascularization in STEMI did not reduce MACE vs Culprit-lesion only PCI: The FULL REVASC Trial
Key Points Researchers compared outcomes in patients with STEMI or very-high-risk non-STEMI (NSTEMI) and multivessel disease who were undergoing primary percutaneous coronary intervention (PCI) of the culprit lesion to receive…
PREVENT: PCI of non-flow-limiting vulnerable plaques reduced MACE compared to medical therapy alone
Key Points: Vulnerable plaques can lead to acute coronary syndromes, but it is unknown whether performing PCI on these lesions improves outcomes. In this RCT, patients with at least one…
PERFORM-TAVR: Home based exercise and protein supplementation improves physical performance in frail adults post-TAVR
Key Points: Many frail patients experience poor physical performance after TAVR, even when the procedure is a technical success. In frail, older patients undergoing TAVR, a combined program of home…
EMBO-ABL: Cryoballoon non-inferior to radiofrequency catheter ablation for AF for silent cerebral events
Key Points: Among AF patients undergoing catheter ablation, cryoballoon was non-inferior compared to radiofrequency for the primary endpoint of silent cerebral embolic events detected on MRI.
RELIEVE HF: Inter-Atrial Shunting Does Not Reduce Symptoms or Improve Prognosis in HF
Key Points: Inter-atrial shunting (IAS) may provide a useful opportunity to dynamically regulate left atrial pressure in heart failure. In the RELIEVE-HF study, IAS was compared with placebo in patients…
SHASTA 2: Novel RNAi Therapeutic Plozasiran Results in Sustained Reduction In Triglycerides in Severe Hypertriglyceridemia
Key Points: Severe hypertriglyceridemia portends high risk of both CVD and acute pancreatitis, but there are limited effective treatment options. A novel RNA interference (RNAi) therapeutic plozasiran can reduce APOC3,…
DanGer Shock: Impella Reduces All-Cause Mortality in STEMI Cardiogenic Shock
Key Points: Cardiogenic shock (CS) mortality remains high despite increased utilization of mechanical circulatory support. Specifically, no randomized data has supported the use of Impella CP in CS. In DanGer…
AT-001, a potent aldose reductase inhibitor, did not improve exercise capacity in diabetic cardiomyopathy with impaired exercise capacity
Key Points: The ARISE-HF trial evaluates the use of AT-001, a potent aldose reductase inhibitor, to reduce the risk of diabetic cardiomyopathy among patients with Type II diabetes. The trial…